InterWest closes $650M fund

Life science VC firm InterWest Partners has closed a $650 million fund. The money will be invested in emerging life sciences and information technology investments. The group aims to invest in 25 to 30 new companies, and will focus on early-stage companies in the U.S.

"For 29 years InterWest has been making successful investments by combining the deep domain experience of our investment team with the vision of outstanding entrepreneurs," said Dr. Arnold L. Oronsky, general partner at InterWest. "We take pride in our collaborative approach to working with portfolio companies to develop important life sciences and IT products that produce thriving businesses." In addition to closing the fund, InterWest announced that Chris Ehrlich, Nina Kjellson and Doug Pepper have been promoted to general partner.

- check out InterWest's release

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."